Status:

COMPLETED

Safety, Tolerability, and Pharmacokinetics (PK) of Single and Multiple Ascending Oral Doses of XEN1101.

Lead Sponsor:

Xenon Pharmaceuticals Inc.

Conditions:

Healthy Volunteers

Eligibility:

All Genders

18-55 years

Phase:

PHASE1

Brief Summary

The XEN1101 Phase 1 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the safety, tolerability and PK of both single ascending doses (SAD) and multiple ascendin...

Detailed Description

Part 1 will study safety, tolerability, PK of single ascending doses (SAD) of XPF-008 as well as the impact and variability of single ascending doses of XPF-008 on TMS. Part 2 will study the safety, ...

Eligibility Criteria

Inclusion

  • Key
  • Healthy male or females aged between 18 and 55 years inclusive with a body mass index (BMI) between 18.50 and 30.00 kg/m2
  • Must agree to use effective methods of contraception, if applicable
  • Able to swallow capsules
  • Able to provide written, personally signed and dated informed consent form (ICF)
  • Key

Exclusion

  • Any history of epileptic seizures
  • Any current and relevant history of significant disease or disorder which, in the opinion of the investigator, may either put the subject at risk, affect clinical or laboratory results, or the subject's ability to participate in the study
  • Answering "yes" to any of the questions within the Columbia Suicide Severity Rating Scale
  • Mental incapacity or lingual barriers precluding adequate understanding, cooperation, and compliance with the study
  • No prescription or over-the-counter (OTC) medications (except hormonal contraception), herbal or dietary supplements OTC medications 14 days prior to dosing to study end
  • No smoking 60 days prior to dosing to study end
  • No soft drugs 3 months prior to Screening and hard drugs 2 years prior to Screening

Key Trial Info

Start Date :

November 13 2017

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 26 2021

Estimated Enrollment :

130 Patients enrolled

Trial Details

Trial ID

NCT03340220

Start Date

November 13 2017

End Date

November 26 2021

Last Update

May 11 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Richmond Pharmacology Ltd.

London, United Kingdom, SE1 1YR